Chapter 19: Drugs for Parkinson Disease

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to this deep dive.

We are so glad you are here with us.

Today we're really framing this as a focused, one -on -one tutoring session, specifically designed to prep you for advanced clinical practice.

Yeah, exactly.

The mission today is to completely unpack Chapter 19 of Lane's Pharmacotherapeutics.

So we're looking at drugs for Parkinson's disease.

Right.

And our roadmap for this session is pretty straightforward.

We are going to start with the underlying pathophysiology,

move into the primary therapeutic goals and then step logically through the major drug classes.

Right.

From levodopa all the way to non -motor symptom management.

And of course, we'll unpack the essential clinical guidelines,

black box warnings, and the patient education priorities along the way.

Because usually when you prescribe a medication in clinical practice, there is this expectation of precision.

It feels a bit like plumbing, right?

Totally.

You find a leak, you patch the leak.

Exactly.

You have a patient with high blood pressure, you give them the diuretic, their fluid volume drops and the pressure normalizes.

It's just a straight line.

It is a very comforting way to practice medicine.

You want that clear cause and a highly predictable effect.

But then you step into the world of neurodegenerative diseases and suddenly you are not a plumber anymore.

Well, you're trying to balance this wildly complicated chemical equation where the variables are constantly shifting.

Yeah.

And the medications you use to fix one problem almost inevitably cause like three more problems down the line.

Managing Parkinson's disease really is the ultimate clinical balancing act.

It's a constantly moving target, which is why you absolutely cannot prescribe these complex regimens safely without deeply understanding the broken machinery you're trying to repair.

Right.

And Parkinson's disease is fundamentally driven by the progressive degeneration of dopaminergic neurons, specifically in a very specific part of the brain called the substantia negra.

And my mind immediately goes to the why.

Like why are those specific neurons dying off while the rest of the brain's hardware stays intact?

Well, it really comes down to a cellular waste disposal failure.

The evidence points heavily to this toxic protein called alpha -synuclein.

Okay.

And usually the body just gets rid of that, right?

Exactly.

In a healthy brain, the body degrades and clears this protein out very efficiently.

But in Parkinson's, due to a mix of genetic vulnerabilities and, you know, possibly environmental toxins,

that degradation system just fails.

So it builds up.

Yeah.

The alpha -synuclein accumulates inside the cell and folds incorrectly.

It forms these neurotoxic fibrils, and over time they clump together into dense masses.

Oh, wow.

If you look at a brain autopsy of a Parkinson's patient, you will literally see these visible clumps inside the neurons.

They're called Lewy bodies, and they are the Hallmark pathology that basically suffocates and kills the cell.

To visualize what that cellular death actually does to the patient's movement, I always like to picture the brain striatum, which is the area controlling movement, as a seesaw.

Oh, that's a great analogy.

Right.

Because for normal, smooth, controlled movement, that seesaw requires perfect equilibrium.

On one side you have dopamine, which acts as the inhibitor.

It's the brakes.

And on the other side you have acetylcholine, or aletrush, which is the excitatory neurotransmitter, so the gas pedal.

Exactly.

Both of these neurochemicals influence the neurons that release GABA, which is the body's main inhibitory neurotransmitter that ultimately controls muscle function.

And that seesaw visualization is incredibly accurate for clinical reasoning.

In the Parkinsonian striatum, the dopamine side of the seesaw is essentially empty.

Because those substantia nigra neurons have died off.

Right.

So because there are no dopamine brakes left, the acetylcholine gas pedal is just stuck to the floor.

This unopposed excitatory influence causes massive overstimulation of those GABA -ergic neurons.

And that overactivity is the direct driver of the classic motor symptoms of Parkinson's, right?

The resting tremor, the severe muscle rigidity, the postural instability.

Yeah.

And bradykinesia, which is that profoundly slowed movement where a patient struggles to even initiate taking a single step.

But the truly wild part of this is the timeline.

The clinical presentation, that tremor or stiffness, is really just the tip of the iceberg, isn't it?

It is.

By the time a patient actually walks into your clinic with a recognizable symptom that prompts a diagnosis,

they have already lost 70 to 80 percent of those dopaminergic neurons.

70 to 80 percent?

Wait, really?

Before they even show symptoms?

Yes.

It is a staggering amount of hidden silent damage.

This neuronal loss takes place over five to 20 years before overt motor symptoms even appear.

Wow.

Which brings us to a very harsh clinical reality.

We have no cure.

None.

Decades of research and hundreds of clinical trials have failed to find a single nerve protective drug that can prevent this damage or, you know, reverse it once the neurons are gone.

So as a clinician, your mindset has to shift entirely.

You are not slowing the disease progression.

Your goal is strictly symptomatic relief.

Exactly.

You are choosing drugs, anti -treating dosages based entirely on improving the patient's ability to carry out their activities of daily living.

Like can they still work?

Walk unassisted, button their shirt, or feed themselves.

Right.

You are just trying to get that seesaw back into a functional, livable balance for as long as possible.

And because we can't cure it, we rely on a strict treatment algorithm to decide which drug to deploy at what stage.

So if we look at the evidence -based guidelines from the American Academy of Neurology and the Moving Disorder Society, how do we decide which drug to use first?

Your initial drug selection depends entirely on symptom severity.

I would assume if a patient comes in with very mild symptoms, maybe a slight hand tremor that's annoying,

but not really interfering with their ability to type or drive, we don't want to bring out the heavy artillery right away.

Precisely.

For mild symptoms, the guidelines recommend starting with MAOB inhibitors.

We'll dig into their mechanism later, but essentially they provide mild symptomatic benefits while carrying far fewer side effects.

But if they present with severe symptoms that are actively threatening their independence.

Then you bypass the mild stuff.

You bring out the heavy hitters immediately.

Treatment should begin with either a levodopa, which is always combined with carbidopa, or a dopamine agonist.

We should probably brief you on the long -term reality of those heavy hitters, though, because it sets the stage for everything else we're going to discuss.

Yeah, that's crucial.

A long -term treatment with levodopa or dopamine agonists is virtually guaranteed to cause two major motor complications down the road.

Right.

First, patients experience off times.

That's an abrupt loss of symptom relief, where the drug just temporarily stops working and the patient freezes up.

And second, they develop drug -induced dyskinesias, which are severe involuntary writhing movements.

This is why managing Parkinson's is so uniquely difficult.

You evasively end up prescribing new drugs entirely, just to fix the side effects of the drugs you prescribed five years ago.

Which is the perfect segue into the absolute cornerstone of Parkinson's treatment, levodopa.

The big one.

The big one.

At the beginning of therapy, levodopa is astonishingly effective.

Roughly 75 % of patients experience a 50 % reduction in symptom severity.

That's massive.

It is so universally effective that if a patient with Parkinsonian symptoms does not respond to levodopa, you actually need to go back and question your initial diagnosis.

Okay, but my immediate instinct here, looking at the pathophysiology,

is to just give the patient a dopamine pill.

If they lack dopamine, why are we giving them levodopa?

Ah, it's the ultimate pharmacological roadblock.

Dopamine physically cannot cross the blood -brain barrier.

The molecule is simply too polar to pass through those tight endothelial junctions.

And also it just bounces right off.

Exactly.

Furthermore, even if we could get it into the brain,

exogenous dopamine has an incredibly short half -life in the bloodstream.

The body would metabolize it almost instantly.

But levodopa is different.

It's a precursor molecule, right?

Yes.

It is uniquely structured to hijack an active transport system, an amino acid pump that carries it safely across the blood -brain barrier.

And once it's inside the central nervous system, it's taken up by the few remaining dopaminergic nerve terminals.

Correct.

Then, local decarboxylase enzymes cleave it and convert it into the active dopamine we so desperately need to push down that side of the seesaw.

But levodopa has its own massive vulnerability, which is the exact reason it is never, ever given a loan in modern practice.

Right.

It's universally combined with a secondary drug called carbidopa.

I love talking about carbidopa because it functions essentially as the ultimate VIP bodyguard.

That's the perfect way to describe it.

If you give a patient levodopa by itself, that pill has to survive a gauntlet of decarboxylase enzymes in the gastrointestinal tract and the peripheral tissues before it ever reaches the brain.

And those peripheral enzymes are ruthless.

They will eagerly destroy 98 % of levodopa.

Only 2 % survives the journey.

And all of that levodopa being converted into dopamine in the peripheral bloodstream causes massive nausea, vomiting, and really dangerous cardiovascular issues like dysrhythmias.

Enter carbidopa.

Now carbidopa has absolutely zero therapeutic effect on its own.

Right.

It doesn't treat Parkinson's at all.

Not at all.

Its sole job is to inhibit those peripheral decarboxylases.

It takes the hit.

By suppressing that peripheral degradation, carbidopa allows 10 % of the levodopa to reach the brain instead of just 2%.

Because carbidopa is doing all that heavy lifting in the periphery, it allows you to reduce the required daily dosage of levodopa by 75%.

Yeah.

You get vastly more drug exactly where you need it and significantly fewer side effects like the nausea and heart palpitations where you don't.

And the brilliance of the design is that carbidopa itself cannot cross the blood -brain barrier.

It stays entirely in the periphery, meaning it doesn't interfere with the conversion of levodopa to dopamine once the levodopa is safely inside the brain.

Now when it comes to the pharmacokinetics of levodopa, there is a massive clinical education point you have to drive home with your patients regarding food.

Yes.

The protein rule.

Exactly.

Levodopa is absorbed in the small intestine, but it relies on that specific amino acid transport pump we mentioned earlier.

This means it has to actively compete with neutral amino acids from the patient's diet for absorption.

And it competes with them again to cross the blood -brain barrier.

Right.

So if a patient sits down and eats a massive high protein meal like a large steak, their bloodstream is suddenly flooded with amino acids.

Those amino acids will completely crowd out the levodopa at the transport gates.

The patient will absorb very little of their medication.

And they will likely experience an abrupt off episode where their tremor and rigidity return almost instantly.

You must educate patients to spread their daily protein consumption evenly across all their meals to maintain steady drug absorption.

Let's address the adverse effects of levodopa because they are profound.

We mentioned dyskinesias earlier, but we really need to emphasize the sheer irony of this.

It is incredibly ironic.

Levodopa is a drug prescribed to restore voluntary movement.

Yet, it causes disabling involuntary movement disorders in about 80 % of patients within the first year of therapy.

We're talking about head bobbing, facial tics, or severe rioting movements of limbs.

You're pushing the dopamine side of the seesaw so hard, so artificially, that it tips entirely too far in the opposite direction.

And then you have the psychiatric effects, which are arguably even harder on the families.

Psychosis develops in about 20 % of patients on levodopa.

Which manifests as visual hallucinations,

vivid, terrifying nightmares,

and intense paranoid ideation.

And if your patient develops psychosis, your clinical reflex might be to reach for an antipsychotic, but you are walking into a massive trap there.

This is one of the most critical safety alerts in Parkinson's management.

You must never use first -generation antipsychotics, like haloperidol, to treat levodopa -induced psychosis.

Because first -generation antipsychotics work primarily by blocking dopamine receptors in the striatum, right?

Exactly.

If you give them to a Parkinson's patient, you will completely nullify the levodopa and severely exacerbate all of their motor symptoms.

You will essentially freeze them in place.

So if they desperately need an antipsychotic, you have to reach for specific second -generation agents, like clozapine or quechapine.

Or there's a drug called pimavancerin, which is specifically approved for Parkinson's disease psychosis.

These drugs either don't block dopamine in the striatum at all, or they block it so weakly that they manage the hallucinations without ruining the patient's modal function.

Ok, so knowing that the levodopa engine eventually burns out and causes these severe dyskinesias, we obviously need alternatives.

That brings us to our next major pharmacological class,

the dopamine receptor agonists.

Right.

If levodopa is a precursor that requires surviving dopaminergic neurons to convert it, we can bypass that dying infrastructure entirely with agonists.

Because dopamine agonists don't need to be converted by any enzymes.

They just cross the blood -brain barrier and directly activate the dopamine receptors in the striatum themselves.

And because they don't seem to cause those disabling dyskinesias quite as quickly as levodopa, they're often the preferred first -line drugs for younger patients who can handle the side effects a bit better than the frail, elderly population.

The agonists are divided into two main categories, right?

Non -ergott derivatives and ernot derivatives.

Yes, but in modern practice, you will almost exclusively prescribe the non -ergott derivatives, which include primupexel, ropinolol, and rhodogatine.

They are highly selective for dopamine receptors.

And the older ergot derivatives, like bromocryptine.

They're rarely used now because they lack that selectivity and carry a serious risk of causing fibrotic complications, particularly valvular heart disease.

Good to know.

But even the highly preferred non -ergott agonists have some truly bizarre adverse effects that require very frank, sometimes uncomfortable, patient education.

Oh, absolutely.

We're talking about sleep attacks.

And this isn't just standard drowsiness.

This is an overwhelming, instantaneous onset of sleep without any warning signs, sometimes while the patient is actively driving a car.

It's terrifying.

And perhaps even more disruptive to a patient's life are the impulse control disorders.

Right.

This is driven entirely by that constant artificial stimulation of the dopamine reward pathways.

About nine months into therapy, patients can develop incredibly severe compulsive behaviors.

We see pathological gambling, where patients drain their life's savings,

binge eating, compulsive shopping, and hypersexuality.

Because you're artificially flooding the brain's novelty -seeking circuits.

You absolutely have to screen the patient for a history of alcohol misuse or impulsive personality traits before prescribing these.

And you have to sit the family down and warn them exactly what behavioral changes to watch out for.

Now, within the non -ergott class, there is one very unique drug you need in your clinical toolkit, apomorphine.

Yes.

But this is not a daily maintenance pill.

It is a subcutaneous rescue pen, structurally similar to an EpiPen, strictly used for severe off -episodes when a patient suddenly loses all mobility and is essentially frozen in place.

But you cannot just prescribe the apomorphine pen and tell them to use it as needed, right?

Definitely not.

Apomorphine causes profound, crippling nausea.

The clinical protocol mandates that you must start the patient on a specific anti -emetic, called trimethybenzimide, three full days prior to their first epimorphine injection to prep their system.

And here is a major clinical safety alert that catches a lot of people off guard.

You might be tempted to prescribe a common, highly effective anti -emetic, like Zofran, which is a serotonin receptor antagonist.

Do not do it.

Right.

Combining apomorphine with any serotonin antagonist can trigger severe, life -threatening hypotension and a complete loss of consciousness.

It is an absolute contraindication.

So we have our dopamine replacers, levodopa, and our direct agonists.

But what happens when the disease progresses and the levodopa starts wearing off too fast between doses?

We have to find a way to make the dopamine stick around longer.

We use extenders.

Exactly.

The first group of extenders are the COMT inhibitors.

These include entocopone, tolcopone, and opocopone.

COMT is an enzyme that naturally breaks down levodopa in the peripheral bloodstream, right?

Yep.

By inhibiting COMT, we block that degradation, effectively prolonging levodopa's half -life, so a larger percentage of the dose makes it into the brain.

In daily practice, you will almost always prescribe entocopone.

It's safe, it's effective, and the main patient education point is just to warn them that it might harmlessly turn their urine a brownish -orange color.

Right.

No big deal there.

What you must be incredibly cautious with, however, is tolcopone.

Because tolcopone has a severe black box warning for a fatal hepatocellular injury,

massive liver failure.

It's strictly a drug of last resort.

If a patient's symptoms are so uncontrolled that you absolutely have to prescribe tolcopone, you are mandated to meticulously monitor their AST and ALT liver enzymes every two to four weeks for the first six months.

And if those enzymes elevate even slightly beyond normal limits, you pull the drug immediately and never trial it again.

The other group of extenders are the MAOB inhibitors, which include selagelin, risagelin, and siphonamide.

While the COMT inhibitors work out in the peripheral bloodstream, the MAOB inhibitors work inside the brain itself.

They selectively inhibit the specific enzyme that breaks down active dopamine in the striatum, presuming whatever dopamine is floating around and reducing those unpredictable off -times.

But again, you're manipulating complex brain chemistry, so there are quirks.

Selagelin, for instance, metabolizes directly into all amphetamine and L -methamphetamine in the body.

Unsurprisingly, this causes severe central nervous system excitation and profound insomnia.

You have to explicitly tell the patient to take their last dose of selagelin no later than noon, or they will be awake all night.

And we really have to talk about the severe dietary restrictions associated with this class.

Yes.

At the recommended clinical doses, these drugs are highly selective for the MAOB enzyme, but at higher doses, they lose that selectivity and start inhibiting MAOA as well.

And MAOA is the enzyme responsible for breaking down norepinephrine and serotonin in the gut.

Right.

If you inhibit MAOA and the patient eats foods rich in a compound called tiramine, things like aged blue cheese, tap beer, cured meats, the tiramine builds up and triggers a massive, potentially lethal, hypertensive crisis.

That dietary restriction is a non -negotiable education point if you push the dose.

There is also a critical black box warning here that you wouldn't intuitively expect with a movement disorder drug.

Yeah, because they act similarly to certain antidepressants, MAOB inhibitors carry an increased risk of triggering suicidal thoughts and behaviors, particularly in patients under 24 years old.

Okay, so we've pumped the patient full of levodopa to get them moving, and now they are writhing with dyskinesias.

We've effectively created a new, highly disruptive disease to treat the old one.

How do we undo this?

We looked to a drug called amantadine.

Amantadine is a fascinating pharmacological accident.

It's an NMDA receptor antagonist that was originally developed as an antiviral drug to fight influenza.

But clinicians noticed it seemed to promote the release of dopamine and block its reuptake.

Today, it is the only drug currently recommended specifically to treat those severe levodopa -induced dyskinesias.

The main patient education point for amantadine is warning them about lavado reticularis.

This is a condition where the patient develops a mottled, purplish, lace -like skin discoloration, usually on their legs, after a month or so of therapy.

It looks alarming to the patient, but you just reassure them it is completely benign and will fade away when the drug is stopped.

It's also worth mentioning there's a newer class of drug out there called an adenosine receptor antagonist, specifically isdramaviline.

Yeah, the theoretical mechanism is that adenosine naturally opposes dopamine in the brain, so blocking adenosine should theoretically help relieve symptoms.

However, its real -world efficacy is highly controversial.

Right, the current clinical guidelines remain very skeptical, often advising against its routine use.

But what if we take a step back and look at our seesaw analogy again?

Okay, let's do it.

If the disease has progressed so far that we simply can't raise the dopamine breaks enough, can we approach the problem from the other side?

Can we just take our foot off the acetylcholine gas pedal?

We absolutely can, and we do, using centrally acting anti -cholinergic drugs like benztropine and trihexaphenidol.

By blocking muscarinic receptors directly in this triatum, we decrease that runaway excitatory acetylcholine activity.

Historically, these are actually the oldest Parkinson's medications we have, dating all the way back to the 1800s.

And they are phenomenal for reducing the resting tremor, particularly in younger patients whose primary symptom is shaking rather than stiffness.

But you want to aggressively avoid these in older adults?

They are firmly on the Beers criteria for potentially inappropriate medication use in older adults.

An aging brain simply does not tolerate the central anti -cholinergic effects.

It will trigger severe confusion, delusions, and hallucinations.

Furthermore, the peripheral anti -cholinergic effects can precipitate acute glaucoma and cause dangerous urinary retention.

Which brings us to the final, and often most overlooked, piece of the clinical puzzle, non -motor symptoms.

Parkinson's disease is famous in the public eye for its motor deficits, the tremor of the shuffling gait.

But 90 % of patients experience profound non -motor symptoms that can destroy their quality of life.

Your clinical troubleshooting has to address the entirety of the patient's failing nervous system.

You're dealing with widespread autonomic nervous system failure.

For example, orthostatic hypotension is incredibly common and represents a massive fall risk.

A patient stands up, their blood pressure plummets, and they hit the floor.

To manage this, you can prescribe droxodopa, which is an alpha and beta adrenergic agonist that helps constrict the blood vessels and keep their pressure up when they change positions.

You also see severe gastrointestinal and secretory issues.

For severe drooling, which can lead to aspiration, we use localized botulinum toxin injections or an anticholinergic glycopyrrolate.

And for the severe constipation caused by the slow, rigid GI tract, an osmotic laxative like a PEG solution, think Merilax is highly recommended over stimulant laxatives.

The sleep disturbances are also brutal.

For the extreme daytime sleepiness, we might use modafinil, which is a central nervous system stimulant.

But for the insomnia that keeps them up all night, melatonin is recommended to help regulate the circadian sleep cycle without throwing heavy addictive sedatives into an already complex and fragile drug regimen.

And finally, the neuropsychiatric symptoms.

50 % of these patients will develop clinical depression as the disease physically alters their brain chemistry.

The guidelines often point to amitryptaline, but you have to monitor closely for those anticholinergic side effects we just warned about.

And for the 40 % of patients who eventually develop Parkinson's disease dementia, you

Right.

These help raise acetylcholine levels in the cortex, producing modest cognitive improvements without necessarily making the motor symptoms worse.

If we synthesize everything we've talked about, the clinical framework really comes down to this.

You must understand the root pathophysiology so you can set realistic expectations with your patient.

You choose your primary weapon based on symptom severity and the patient's age.

You buy time and extend the life of that drug with COMT or MAOB inhibitors when it inevitably starts to fail.

And you aggressively monitor for wild side effects, from sudden sleep attacks to gambling addictions to psychosis, constantly adjusting the regimen to keep that seesaw from crashing to the ground.

It is exhausting, meticulous work.

And that leads to a rather provocative final thought for you to ponder.

Everything we have discussed today, the levodopa, the agonists, the extenders, the rescue pens, it is all just symptomatic management.

It's patching a leaky roof while the foundation of the house continues to crumble.

Exactly.

The root cause is the cellular failure to degrade alpha -c -nuclein.

So what happens to the future of pharmacology and to millions of patients globally when we finally develop a drug that can locate and clear those neurotoxic fibrils from the brain before the Lewy bodies ever have a chance to form?

That is the holy grail.

To fix the plumbing before the house floods.

Until then, you have the pharmacological tools to manage the muddy waters and keep your patients moving for as long as possible.

Thanks for joining us on this deep dive from all of us at the Last Minute Lecture Team.